TEVA beats on second-quarter earnings but misses on sales. The company lowers 2021 sales view. It expects to settle opioid litigation in the coming year.
Thank you, Ella, and thank you, everyone, for joining us today to discuss Teva's second-quarter 2021 financial results. Joining me on today's call is Kare Schultz, Teva's chief executive officer; Eli Kalif, Teva's chief financial officer; and Brendan O'Grady, Teva's head of North America commercial.
TEL AVIV, Israel, July 28, 2021--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) released a new report highlighting the billions of dollars saved by the healthcare system due to its generic medicines, and the Company’s contribution to economies in 2020.